Perceiv is an AI-based digital biomarkers company specializing in the field of precision medicine. We are dedicated to help improving and saving patient lives through more efficient, accurate, subject targeting, and objective prognosis through advanced machine learning algorithms.
Diseases are more complex than they appear resulting in problems when finding the right population to treat and demonstrate treatment efficacy. We help pharmaceutical companies improve their chances of success by identifying the right subjects for their clinical trials using our AI-driven precision medicine platform. We specialize in the identification of subpopulations of interest in heterogeneous data and complex diseases.
Perceiv is currently developing applications for Alzheimer's disease and CNS-related indications.
Our proprietary platform enables us to ingest various types of data to better characterize individuals (imaging, genetic, phenotypic and clinical variables).
Identify with very high precision groups of subjects in heterogeneous populations.
Improve treatment success by appropriate subject selection for clinical trials.
Reduce clinical trial cost using precision enrollment of patients.
Prognostic and diagnostic based on clinical data.
Improve treatment outcome by appropriate targeting of individuals.
Combine multimodal biomarkers using our proprietary platform.
Dr. Dansereau has over a decade of experience doing machine learning research applied to neuroimaging and medical data. Ph.D. in Computer Science from University of Montreal. Master in Biomedical Engineering from McGill University. Bachelor degree in Electrical Engineering.
Deep Learning researcher from MILA supervised by Pascal Vincent (Facebook) and Yoshua Bengio. Extensive experience with medical data.
Postdoctoral fellow at the National University of Singapore. Expertise in multimodal imaging of neurological diseases and psychiatric disorders.
Director of the Alzheimer’s Disease Research Unit at McGill University, Montreal, Canada. Professor of Neurology & Neurosurgery, Psychiatry and Medicine at McGill University, Montreal, Canada. Member, Douglas Mental Health University Institute’s Research Center. Membre Associé, Institut Universitaire de Gériatrie, Université de Montréal.
Cardiologist, former president of CAE healthcare, professor of medicine and well-published researcher. Accomplished executive and board member of The Royal College International. Simulation Hall of Fame inductee (2018).
Executive with 20+ years of diversified international Medical Affairs experience at Merck, Novartis, Celgene now BMS and Intercept Pharma. Extensive medical-marketing experience across therapeutic areas including oncology, cardiology, liver and rare diseases with several blockbusters and pipeline compounds in pre/post-launch initiatives.
Scientific director of the functional imaging unit. Researcher at the CRIUGM, Computer Science and operations research, University of Montreal. Co-lead of the biomarker team of the Canadian Consortium on Neurodegeneration in Aging (CCNA).
Chief Medical Officer at Shanghai Green Valley Pharmaceutical, Founding member and former Executive Dir, Critical Path Institute Coalition Against Major Diseases (CAMD), AVP Merck, Pfizer and AstraZeneca. Pharmaceutical physician executive with over 16 years of broad experience across multiple critical functions including clinical research and medical affairs, clinical operations, regulatory affairs, quality & compliance, pharmacovigilance, and portfolio & project management/leadership.
Expertise in financial, health and medical technology sectors. Experienced in startup, growth and governance of companies. Board member of Montreal CHUM hospital.
Founder and chief scientific officer at KalGene Pharmaceuticals. University and industrial research scientist.
Researcher at University of Montreal. Multimodal expertise in genomics, proteomics, metabolomics and imaging with a focus on neurodegenerative pathology. Expertise in neurovascular coupling and a general interest in the heart-brain link to neurodegeneration.